An observational study to evaluate the long‐term outcomes of treatment with etanercept in patients with plaque‐type psoriasis

Abstract

The mean duration of drug-free intervals was relatively short, most patients experienced improvements in disease activity and health-related quality of life within 12 weeks of either continuous or intermittent treatment with etanercept, and there were no new safety signals. ClinicalTrials.gov identifier: NCT00708708.

Real-World Experience with Etanercept Therapy and the Switching Pattern among Korean Patients with Psoriasis after Withdrawal of Etanercept

“…Etanercept is a fully human TNF-α receptor protein that competitively inhibits the TNF-α-mediated inflammatory cascade in patients with psoriasis 1,4 . The common regimen of etanercept for chronic plaque-type psoriasis in Korea involves a biweekly injection of 25 mg of etanercept 1,2 .…”

“…The chronic and recurrent nature of psoriasis often requires long-term continuous treatment 2,3 . As the understanding of the role of the immune mechanism in psoriasis has increased, new biologics have been introduced in the treatment 1,4 . In Korea, infliximab, etanercept, adalimumab, ustekinumab, and secukinumab are available for the treatment of moderate to severe psoriasis.…”

“…In Korea, infliximab, etanercept, adalimumab, ustekinumab, and secukinumab are available for the treatment of moderate to severe psoriasis. Etanercept is a fully human tumor necrosis factor (TNF)-α receptor protein that competitively inhibits the binding of TNF-α to the cell surface receptors, thereby preventing the activation of the TNF-α-mediated inflammatory cascade in patients with psoriasis 1,4 . The efficacy and safety of eta- nercept has been proven in the treatment of psoriasis, and it has been approved for the treatment of moderate to severe psoriasis since 2004 in Korea 1,4 .…”

“…Etanercept is a fully human tumor necrosis factor (TNF)-α receptor protein that competitively inhibits the binding of TNF-α to the cell surface receptors, thereby preventing the activation of the TNF-α-mediated inflammatory cascade in patients with psoriasis 1,4 . The efficacy and safety of eta- nercept has been proven in the treatment of psoriasis, and it has been approved for the treatment of moderate to severe psoriasis since 2004 in Korea 1,4 . The utility of etanercept as an effective form of treatment for moderate to severe psoriasis has been investigated through various clinical trials; however, there have been few studies presenting real-world data focused on the switching pattern of treatment modalities after the discontinuation of etanercept.…”

“…Previously, we reported the effectiveness of a low-dose etanercept therapy combined with systemic medication or phototherapy in Asian patients with non-severe psoriasis in comparison to that in a Western population 1 . In addition, other studies have reported the effectiveness of an intermittent etanercept treatment or a combination treatment with etanercept and acitretin for patients with plaque-type psoriasis 2,4 . Based on these previous studies, it can be inferred that etanercept is used with modified treatment regimens and in combination with other treatment modalities.…”